Sue Tsuda, MD
Medical Oncology · Conway, ARNPI 1275532715
Payments from drug & device makers
What this record shows
It is spread thinly across 21 manufacturers, the largest accounting for just 17.1%. 2025 is the largest year on record at $166, 2.4 times the $70 reported in 2019. That places this record below the midpoint for medical oncology clinicians in AR, where the typical reported total is $1,872.
Across 27 payments — averaging $21.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$99
- Genentech, Inc.$50
- Gilead$44
- Bristol Myers Squibb$35
- Merck$35
- GSK$29
- plus $286 from 15 others
What the payments were for
- Food & beverage$34359%
- Education$23641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 1 | $99 |
| Genentech, Inc. | 1 | $50 |
| Gilead | 3 | $44 |
| Bristol Myers Squibb | 2 | $35 |
| Merck | 2 | $35 |
| GSK | 2 | $29 |
| Adaptive Biotechnologies Corporation | 1 | $28 |
| Lilly USA, LLC | 2 | $27 |
| AstraZeneca | 1 | $26 |
| AbbVie | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Novartis | 1 | $22 |
| Amgen | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Legend Biotech USA Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Beigene USA, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
How this compares
$579 in reported general payments places this provider in the 30th percentile of 20 medical oncology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 87 | $1,489,036 |
| ImbruvicaIbrutinib | 41 | $688,971 |
| OjjaaraMomelotinib Dihydrochloride | 23 | $650,046 |
| InlytaAxitinib | 16 | $304,653 |
| IbrancePalbociclib | 18 | $290,962 |
| TagrissoOsimertinib Mesylate | 12 | $236,406 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $193,585 |
| TafinlarDabrafenib Mesylate | 12 | $178,300 |
| VenclextaVenetoclax | 11 | $132,129 |
| ProcritEpoetin Alfa | 33 | $123,597 |
| EliquisApixaban | 12 | $12,305 |
| XareltoRivaroxaban | 13 | $11,883 |
| Anastrozole | 290 | $3,939 |
| Prochlorperazine Maleate | 81 | $2,087 |
| Letrozole | 142 | $1,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKOjjaara | $29 | $650,04623 claims |
| NovartisMekinist, Tafinlar | $22 | $371,88524 claims |
| AstraZenecaTagrisso | $26 | $236,40612 claims |
| Johnson & JohnsonProcrit, Xarelto | $15 | $135,48146 claims |
| AbbVieVenclexta | $25 | $132,12911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 20 medical oncology providers in Arkansas.
Other medical oncology in Conway
- Muthu KumaranLittle Rock$193K
- Sunilkumar KakadiaHot Springs$31K
- Cesar Gentille SanchezLittle Rock$29K
- Stephen ToothakerSearcy$19K
- Ryan KochSearcy$15K
- Zaki SammanFort Smith$9K
- Kristen SagerMena$8K
- Chen HuangHarrison$5K
- William RobertsonSearcy$4K
- Marc MonteJonesboro$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.